Evogene Stock Current Asset
| EVGN Stock | ILA 606.00 32.00 5.02% |
Evogene fundamentals help investors to digest information that contributes to Evogene's financial success or failures. It also enables traders to predict the movement of Evogene Stock. The fundamental analysis module provides a way to measure Evogene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evogene stock.
Evogene |
Evogene Company Current Asset Analysis
Evogene's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Evogene Current Asset | 95 M |
Most of Evogene's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evogene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Evogene has a Current Asset of 95 M. This is 95.59% lower than that of the Biotechnology sector and 91.04% lower than that of the Health Care industry. The current asset for all Israel stocks is 98.98% higher than that of the company.
Evogene Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evogene's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Evogene could also be used in its relative valuation, which is a method of valuing Evogene by comparing valuation metrics of similar companies.Evogene is currently under evaluation in current asset category among its peers.
Evogene Fundamentals
| Return On Equity | -0.63 | |||
| Return On Asset | -0.28 | |||
| Operating Margin | (24.02) % | |||
| Current Valuation | 8.8 M | |||
| Shares Outstanding | 41.22 M | |||
| Shares Owned By Insiders | 3.58 % | |||
| Shares Owned By Institutions | 3.37 % | |||
| Price To Book | 0.93 X | |||
| Price To Sales | 73.01 X | |||
| Revenue | 930 K | |||
| Gross Profit | 163 K | |||
| EBITDA | (26.78 M) | |||
| Net Income | (27.79 M) | |||
| Cash And Equivalents | 65.36 M | |||
| Cash Per Share | 1.61 X | |||
| Total Debt | 2.39 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 12.74 X | |||
| Book Value Per Share | 0.74 X | |||
| Cash Flow From Operations | (24.72 M) | |||
| Earnings Per Share | (0.72) X | |||
| Target Price | 5.0 | |||
| Number Of Employees | 133 | |||
| Beta | 0.9 | |||
| Market Capitalization | 121.59 M | |||
| Total Asset | 76.3 M | |||
| Retained Earnings | (90 M) | |||
| Working Capital | 89 M | |||
| Current Asset | 95 M | |||
| Current Liabilities | 6 M | |||
| Z Score | 29.8 | |||
| Net Asset | 76.3 M |
About Evogene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evogene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evogene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evogene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Evogene Stock
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Evogene Stock refer to our How to Trade Evogene Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.